Stemline is a commercial-stage biopharmaceutical company committed to applying our scientific leadership and commercial expertise to transform the lives of patients with cancer. ELZONRIS a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN. In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). Inspired by the goal to improve outcomes for patients with unmet medical needs, Stemline is driven to discover and develop innovative therapeutics for the treatment of cancer. Currently our clinical-stage product candidates in include ELZONRIS, SL-701 and SL801.
View Top Employees from Stemline Therapeutics| Website | http://www.stemline.com |
| Ticker | STML |
| Revenue | $43.2 million |
| Funding | $33.9 million |
| Employees | 460 (387 on RocketReach) |
| Founded | 2003 |
| Address | 750 Lexington Avenue 11th Floor, New York, New York 10022, US |
| Phone | (646) 502-2310 |
| Fax | (646) 389-0968 |
| Technologies |
JavaScript,
HTML,
PHP
+16 more
(view full list)
|
| Industry | Biotechnology, Pharmaceuticals, Healthcare, Science and Engineering, Therapeutic Devices, Health Care, Health Diagnostics |
| Web Rank | 5 Million |
| Keywords | Cancer, Targeted Cancer Therapies, Biopharmaceuticals, Therapeutic Activities, Clinical Trials |
| Competitors | Calithera Biosciences, G1 Therapeutics, Inc., Otonomy, Inc, Verastem Oncology, Visterra Inc. |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325412 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular Stemline Therapeutics employee's phone or email?
Stemline Therapeutics Questions
The Stemline Therapeutics annual revenue was $43.2 million in 2024.
David Gionco is the Vice President of Finance and Chief Accounting Officer of Stemline Therapeutics.
387 people are employed at Stemline Therapeutics.
Stemline Therapeutics is based in New York, New York.
The NAICS codes for Stemline Therapeutics are [325412, 325, 32541, 3254, 32].
The SIC codes for Stemline Therapeutics are [283, 28].
Top Stemline Therapeutics Employees
-
45+
-
52
-
ViewKathy Theall
Vice President of Clinical Development, Breast Cancer at Stemline Therapeutics
Cambridge, MA, US25+ -
ViewJeffrey Levitt
SVP, General Counsel and Chief Compliance Officer at Stemline Therapeutics
Fairfield, CT, US5+3
Related Companies
